Heparin-induced thrombocytopenia: A clinicopathologic syndrome

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 439-447

  Warkentin, Theodore E ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; IMMUNOGLOBULIN G; THROMBOCYTE FACTOR 4;

CONFERENCE PAPER; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0032742808     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615864     Document Type: Conference Paper

References (65)

1. Roberts B, Rosato FE, Rosato EF. Heparin-a cause of arterial emboli? Surgery. 1964;5:803-808.
2. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg. 1958;76:219-227.
3. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet. 1973;136:409-416.
4. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia: Eight cases with thrombotic-hemorrhagic complications. Am Surg. 1977;186.752-758.
5. Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia (letter). Thromb Haemost. 1992; 68:95-96.
6. Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247-251.
7. Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: Laboratory studies. Blood. 1988;72:925-930.
8. Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994; 84:3691-3699.
9. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987; 316:581-589.
10. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994; 93:81-88.
11. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
12. Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 1992;120:371-379.
13. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocy-topenia. Thromb Haemost. 1991;66:734-736.
14. Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion. 1994;34:381-385.
15. Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peynaud-Debayle E, Dreyfus M, Meyer D. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost. 1995;73:21-28.
16. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost. 1998;79:1-7.
17. Warkentin TE. The clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, Inc. In press.
18. Warkentin TE. Pseudo-heparin-induced thrombocytopenia: Insights into the pathogenesis of thrombosis. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York: Marcel Dekker, Inc. In press.
19. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980;65:64-73.
20. Warkentin TE, Kelton JG. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Bounameaux H, ed: Low Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. New York: Marcel Dekker, Inc.; 1994:75-127.
21. Balduini CL, Noris P, Bertolino G, Previtali M. Heparin modifies platelet count and function in patients who have undergone thrombolytic therapy for acute myocardial infraction (letter). Thromb Haemost. 1993;69:522-523.
22. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
23. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfraction-ated heparin. N Engl J Med. 1995; 332:1330-1335.
24. Warkentin TE, Levine MN, Hirsh J, Klama LN, Kelton JG. Formation of heparin-induced thrombocytopenia IgG without thrombocytopenia: Analysis of a clinical trial (abstract). Blood. 1996;86(Suppl 1):537a.
25. Lee DP, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, Inc. In press.
26. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35(Suppl 4):9-16.
27. Ganzer D, Gutezeit A, Mayer G, Greinacher A, Eichler P. Thromboembolieprophylaxe als ausöser thrombembolischer komplicationen. Eine untersuchung zur inzidenz der heparin-induzierten thrombozytopenie (HIT) typ II. Z Orthop Ihre Grenzgeb. 1997;135:543-549.
28. Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996;92:494-497.
29. Hach-Wunderle V, Kainer K, Krug B, Müller-Berghaus G, Pötzsch B. Heparin-associated thrombosis despite normal platelet counts (letter). Lancet. 1994;344:469-470.
30. Klement D, Rammos S, van Kries R, Kirschke W, Kniemeyer HW, Greinacher A. Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr. 1996;155:11-14.
31. Warkentin TE, Greinacher A. Laboratory testing for HIT antibodies. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. New York: Marcel Dekker, Inc. In press.
32. Griffiths E, Dzik WH. Assays for heparin-induced thrombocytopenia. Transfus Med. 1997;7:1-11.
33. Warkentin TE, Simpson PJ, Sheppard JI, Moore JC, Horsewood P, Kelton JG. A comparison of activation and antigen assays to diagnose heparin-induced thrombocytopenia (HIT). J Autoimmun. 1999;Suppl:88.
34. Eichler P, Budde U, Haas S, Kroll H, Loreth RM, Meyer O, Pachmann U, Pötzsch B, Schabel A, Albrecht D, Greinacher A. First workshop for detection of HIT antibodies: Validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost. In press.
35. Collins JL, Aster RH, Moghaddam M, Piotrowski MA, Strauss TR, McFarland JG. Diagnostic testing for heparin-induced thrombocytopenia (HIT): An enhanced platelet factor 4 complex enzyme linked immunosorbent assay (PF ELISA) (abstract). Blood. 1997;90(Suppl 1):461a.
36. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost. 1998;80:292-297.
37. Favaloro EJ, Bemal-Hoyos E, Exner T, Koutts J. Heparin-induced thrombocytopenia: Laboratory investigation and confirmation of diagnosis. Pathology. 1992;24:177-183.
38. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69:344-350.
39. 14C-serotonin assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1995;104:648-654.
40. Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95:1242-1246.
41. Look KA, Sahud M, Flaherty S, Zehnder JL. Heparin-induced platelet aggregation vs platelet factor 4 enzyme-linked immunosorbent assay in the diagnosis of heparin-induced thrombocytopenia-thrombosis. Am J Clin Pathol. 1997;108:78-82.
42. Amiral J, Wolf M, Fischer A-M, Boyer-Neumann C, Vissac A-M, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol. 1996;92:954-959.
43. Amiral J, Marfaing-Koka A, Wolf M, Alessi MC, Tardy B, Boyer-Neumann C, Vissac AM, Fressinaud E, Poncz M, Meyer D. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-induced thrombocytopenia. Blood. 1996;88:410-416.
44. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med. 1996;128:376-383.
45. Warkentin TE, Kelton JG. Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: Absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT (abstract). Blood. 1998;92(Suppl 1):182a.
46. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med. 1984;100:535-540.
47. Greinacher A, Warkentin TE. Treatment for heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York: Marcel Dekker, Inc. In press.
48. Pötzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation on patients with heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York: Marcel Dekker, Inc. In press.
49. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997;56:12-16.
50. Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution. J Vasc Surg. 1986;4:522-528.
51. Warkentin TE, Hong AP. Frequency of upper limb deep venous thrombosis (UL-DVT) in relation to central venous catheter (CVC) use in patients with heparin-induced thrombocytopenia (HIT): Evidence for interaction of systemic (HIT) and local (CVC) prothrombotic risk factors (abstract). Blood. 1998;92(Suppl 1):500a-501a.
52. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Veiten HG, Pötzsch B, for the HIT-investigators group. Recombinant hirudin (lepirudin) provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia type II - a prospective study. Circulation. In press.
53. Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev. 1996;10:249-258.
54. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812.
55. Gupta AK, Kovacs MJ, Sauder DN. Heparin-induced thrombocytopenia. Ann Pharmacother. 1998;32:55-59.
56. Meyer-Lindenberg A, Quenzel E-M, Bierhoff E, Wolff H, Schindler E, Biniek R. Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia. Eur Neurol. 1997;37:191-192.
57. Ernest D, Fisher MM. Heparin-induced thrombocytopaenia complicated by bilateral adrenal haemorrhage. Intensive Care Med. 1991;17:238-240.
58. Platell CFE, Tan EGC. Hypersensitivity reactions to heparin: Delayed onset thrombocytopenia and necrotizing skin lesions. Aust NZ J Surg. 1986;56:621-623.
59. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 92:494-497, 1996a.
60. Sallah S, Thomas DP, Roberts HR,. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost 1997; 78:758-790.
61. Warkentin TE. Heparin-induced thrombocytopenia, heparin-induced skin lesions, and arterial thrombosis. Thromb Haemost 77 (Suppl.):562, 1997.
62. Warkentin TE, Sikov WM, Lillicrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol 1999; in press.
63. Popov D. Zarrabi MH, Foda H, Graber M. Pseudopulmonary embolism: acute respiratory distress in the syndrom of heparin-induced thrombocytopenia. Am J Kidney Dis 29: 449-452, 1997.
64. Warkentin TE, Soutar RL, Panju A. Ginsberg JS. Acute systemic reactions to intravenous bolus heparin therapy: Characterization and relationship to heparin-induced thrombocytopenia. Blood 1992; 80(Suppl. 1):160a (abstract).
65. Ling E, Warkentin TE. Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia. Anesthesiology 1998; 89:1567-1569.